Literature DB >> 24115136

The global need to define normality: the 99th percentile value of cardiac troponin.

Yader Sandoval1, Fred S Apple.   

Abstract

BACKGROUND: How to select a presumably normal population for the establishment of 99th percentile cutoffs for cardiac troponin assays has not been adequately addressed. Lack of attention to this question can result in misleading medical decision cutoffs. CONTENT: From our review of the peer-reviewed literature, including international recommendations, no uniform procedure is followed and no uniform guideline has been published by experts or regulatory agencies to guide researchers or manufacturers of cardiac troponin assays in their quest to define the health or "normality" of a reference population that is used to establish an accurate 99th percentile value. As we progress globally into the era of high-sensitivity cardiac troponin assays, we propose several suggested approaches to define presumably normal individuals by use of clinical and biomarker surrogates.
SUMMARY: Our uniform approach to defining who is normal and who may not be normal will help to define diagnostic and risk outcomes assessments in the management of patients with suspected myocardial injury, both for use in current clinical practice and clinical research, as well as for the potential future use of cardiac troponin in primary prevention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24115136     DOI: 10.1373/clinchem.2013.211706

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  20 in total

1.  Cardiac biomarkers of acute coronary syndrome: from history to high-sensitive cardiac troponin.

Authors:  Mario Plebani; Giorgia Antonelli; Martina Zaninotto
Journal:  Intern Emerg Med       Date:  2017-02-17       Impact factor: 3.397

2.  Diabetes mellitus, prediabetes, and incidence of subclinical myocardial damage.

Authors:  Elizabeth Selvin; Mariana Lazo; Yuan Chen; Lu Shen; Jonathan Rubin; John W McEvoy; Ron C Hoogeveen; A Richey Sharrett; Christie M Ballantyne; Josef Coresh
Journal:  Circulation       Date:  2014-08-22       Impact factor: 29.690

3.  Typical rise and fall of troponin in (peri-procedural) myocardial infarction: A systematic review.

Authors:  Dianne van Beek; Bas van Zaane; Marjolein Looije; Linda Peelen; Wilton van Klei
Journal:  World J Cardiol       Date:  2016-03-26

Review 4.  High-sensitivity cardiac troponin testing in routine practice: economic and organizational advantages.

Authors:  Claudio Galli; Giuseppe Lippi
Journal:  Ann Transl Med       Date:  2016-07

Review 5.  The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform.

Authors:  Daniel Soetkamp; Koen Raedschelders; Mitra Mastali; Kimia Sobhani; C Noel Bairey Merz; Jennifer Van Eyk
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

6.  Frequency histograms of three high-sensitivity cardiac troponin assays in a reference population.

Authors:  Hanwool Cho; Hyunjung Kim; Jehoon Lee; Soo-Young Kim; Hae Kyung Lee; Hi Jeong Kwon; Yeongsic Kim
Journal:  J Clin Lab Anal       Date:  2022-04-20       Impact factor: 3.124

7.  Optimal Cutoff Levels of More Sensitive Cardiac Troponin Assays for the Early Diagnosis of Myocardial Infarction in Patients With Renal Dysfunction.

Authors:  Raphael Twerenbold; Karin Wildi; Cedric Jaeger; Maria Rubini Gimenez; Miriam Reiter; Tobias Reichlin; Astrid Walukiewicz; Mathias Gugala; Lian Krivoshei; Nadine Marti; Zoraida Moreno Weidmann; Petra Hillinger; Christian Puelacher; Katharina Rentsch; Ursina Honegger; Carmela Schumacher; Felicitas Zurbriggen; Michael Freese; Claudia Stelzig; Isabel Campodarve; Stefano Bassetti; Stefan Osswald; Christian Mueller
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

8.  Portable nanoporous electrical biosensor for ultrasensitive detection of Troponin-T.

Authors:  Nandhinee Radha Shanmugam; Anjan Panneer Selvam; Thomas W Barrett; Steven C Kazmierczak; Milin Nilesh Rana; Shalini Prasad
Journal:  Future Sci OA       Date:  2015-11-01

9.  Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers.

Authors:  Paul Collinson
Journal:  EJIFCC       Date:  2015-08-24

10.  Transitioning high sensitivity cardiac troponin I (hs-cTnI) into routine diagnostic use: More than just a sensitivity issue.

Authors:  Graham R Lee; Tara Ca Browne; Berna Guest; Imran Khan; Eamon Murphy; Catherine McGorrian; Niall G Mahon; Maria C Fitzgibbon
Journal:  Pract Lab Med       Date:  2016-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.